These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 15475431

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Chromosome 20q13.2 gain may predict intravesical recurrence after nephroureterectomy in upper urinary tract urothelial tumors.
    Akao J, Matsuyama H, Yamamoto Y, Sasaki K, Naito K.
    Clin Cancer Res; 2006 Dec 01; 12(23):7004-8. PubMed ID: 17145821
    [Abstract] [Full Text] [Related]

  • 3. Intercellular centrosome number is correlated with the copy number of chromosomes in bladder cancer.
    Yamamoto Y, Eguchi S, Junpei A, Nagao K, Sakano S, Furuya T, Oga A, Kawauchi S, Sasaki K, Matsuyama H.
    Cancer Genet Cytogenet; 2009 May 01; 191(1):38-42. PubMed ID: 19389507
    [Abstract] [Full Text] [Related]

  • 4. Numerical aberrations of chromosome 17 and the 9p21 locus are independent predictors of tumor recurrence in non-invasive transitional cell carcinoma of the urinary bladder.
    Krüger S, Mess F, Böhle A, Feller AC.
    Int J Oncol; 2003 Jul 01; 23(1):41-8. PubMed ID: 12792774
    [Abstract] [Full Text] [Related]

  • 5. [Clinical value of aneusomy of chromosomes in exfoliated urothelial cells to predict the recurrence of superficial bladder cancer after complete transurethral resection].
    Bao QB, Liu J, Sun HB, Su JH, Zhu JG, Lin JZ.
    Zhonghua Yi Xue Za Zhi; 2009 Mar 03; 89(8):548-51. PubMed ID: 19567078
    [Abstract] [Full Text] [Related]

  • 6. Noninvasive detection of alterations in chromosome numbers in urinary bladder cancer cells, using fluorescence in situ hybridization.
    Okamura T, Umemoto Y, Yasui T, Saiki S, Kuroda H, Kotoh S, Kamizaki H.
    Int J Clin Oncol; 2004 Oct 03; 9(5):373-7. PubMed ID: 15549587
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of BUBR1 is associated with chromosomal instability in bladder cancer.
    Yamamoto Y, Matsuyama H, Chochi Y, Okuda M, Kawauchi S, Inoue R, Furuya T, Oga A, Naito K, Sasaki K.
    Cancer Genet Cytogenet; 2007 Apr 01; 174(1):42-7. PubMed ID: 17350465
    [Abstract] [Full Text] [Related]

  • 8. Centrosome amplification as a putative prognostic biomarker for the classification of urothelial carcinomas.
    Yamamoto Y, Misumi T, Eguchi S, Chochi Y, Kitahara S, Nakao M, Nagao K, Hara T, Sakano S, Furuya T, Oga A, Kawauchi S, Sasaki K, Matsuyama H.
    Hum Pathol; 2011 Dec 01; 42(12):1923-30. PubMed ID: 21683985
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P, Herrmann F, Coassin M, Guillou L, Iselin CE.
    Cancer; 2003 Oct 15; 98(8):1649-57. PubMed ID: 14534881
    [Abstract] [Full Text] [Related]

  • 13. Recurrence and progression in patients with non-muscle invasive bladder cancer: prognostic models including multicolor fluorescence in situ hybridization molecular grading.
    Lodde M, Mian C, Mayr R, Comploj E, Trenti E, Melotti R, Campodonico F, Maffezzini M, Fritsche HM, Pycha A.
    Int J Urol; 2014 Oct 15; 21(10):968-72. PubMed ID: 24947145
    [Abstract] [Full Text] [Related]

  • 14. Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study.
    Wolman SR, Goldman B, Slovak ML, Tangen C, Persons DL, Wood D.
    Cancer Genet Cytogenet; 2007 Jul 01; 176(1):22-7. PubMed ID: 17574960
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Numerical abnormalities of chromosomes 17 and 18 in sporadic colorectal cancer: Incidence and correlation with clinical and biological findings and the prognosis of the disease.
    Garcia J, Duran A, Tabernero MD, Garcia Plaza A, Flores Corral T, Najera ML, Gomez-Alonso A, Orfao A.
    Cytometry B Clin Cytom; 2003 Jan 01; 51(1):14-20. PubMed ID: 12500293
    [Abstract] [Full Text] [Related]

  • 18. [The relationships among DNA ploidy type determined by laser scanning cytometry, the overexpression of p53 protein and the numerical aberrations of chromosome 7 in bladder cancer].
    Kawamura K, Ikeda R, Suzuki K.
    Hinyokika Kiyo; 2000 Jun 01; 46(6):377-83. PubMed ID: 10934605
    [Abstract] [Full Text] [Related]

  • 19. Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations.
    Zhang FF, Arber DA, Wilson TG, Kawachi MH, Slovak ML.
    Clin Cancer Res; 1997 Dec 01; 3(12 Pt 1):2317-28. PubMed ID: 9815630
    [Abstract] [Full Text] [Related]

  • 20. XIAP as a prognostic marker of early recurrence of nonmuscular invasive bladder cancer.
    Li M, Song T, Yin ZF, Na YQ.
    Chin Med J (Engl); 2007 Mar 20; 120(6):469-73. PubMed ID: 17439739
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.